FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285590921> ?p ?o ?g. }

• W4285590921 endingPage "939" @default.
• W4285590921 startingPage "931" @default.
• W4285590921 abstract "The Omicron variant (B.1.1.529) of SARS-CoV-2, the virus that causes COVID-19, was first identified in the United States in November 2021, with the BA.1 sublineage (including BA.1.1) causing the largest surge in COVID-19 cases to date. Omicron sublineages BA.2 and BA.2.12.1 emerged later and by late April 2022, accounted for most cases.* Estimates of COVID-19 vaccine effectiveness (VE) can be reduced by newly emerging variants or sublineages that evade vaccine-induced immunity (1), protection from previous SARS-CoV-2 infection in unvaccinated persons (2), or increasing time since vaccination (3). Real-world data comparing VE during the periods when the BA.1 and BA.2/BA.2.12.1 predominated (BA.1 period and BA.2/BA.2.12.1 period, respectively) are limited. The VISION network† examined 214,487 emergency department/urgent care (ED/UC) visits and 58,782 hospitalizations with a COVID-19-like illness§ diagnosis among 10 states during December 18, 2021-June 10, 2022, to evaluate VE of 2, 3, and 4 doses of mRNA COVID-19 vaccines (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) compared with no vaccination among adults without immunocompromising conditions. VE against COVID-19-associated hospitalization 7-119 days and ≥120 days after receipt of dose 3 was 92% (95% CI = 91%-93%) and 85% (95% CI = 81%-89%), respectively, during the BA.1 period, compared with 69% (95% CI = 58%-76%) and 52% (95% CI = 44%-59%), respectively, during the BA.2/BA.2.12.1 period. Patterns were similar for ED/UC encounters. Among adults aged ≥50 years, VE against COVID-19-associated hospitalization ≥120 days after receipt of dose 3 was 55% (95% CI = 46%-62%) and ≥7 days (median = 27 days) after a fourth dose was 80% (95% CI = 71%-85%) during BA.2/BA.2.12.1 predominance. Immunocompetent persons should receive recommended COVID-19 booster doses to prevent moderate to severe COVID-19, including a first booster dose for all eligible persons and second booster dose for adults aged ≥50 years at least 4 months after an initial booster dose. Booster doses should be obtained immediately when persons become eligible.¶." @default.
• W4285590921 created "2022-07-16" @default.
• W4285590921 creator A5000178488 @default.
• W4285590921 creator A5004523264 @default.
• W4285590921 creator A5005759933 @default.
• W4285590921 creator A5005960274 @default.
• W4285590921 creator A5006012150 @default.
• W4285590921 creator A5006755486 @default.
• W4285590921 creator A5016019091 @default.
• W4285590921 creator A5016734595 @default.
• W4285590921 creator A5020349673 @default.
• W4285590921 creator A5020614173 @default.
• W4285590921 creator A5022164471 @default.
• W4285590921 creator A5027374619 @default.
• W4285590921 creator A5027395964 @default.
• W4285590921 creator A5028068827 @default.
• W4285590921 creator A5033960636 @default.
• W4285590921 creator A5034478332 @default.
• W4285590921 creator A5034545940 @default.
• W4285590921 creator A5037638028 @default.
• W4285590921 creator A5038160777 @default.
• W4285590921 creator A5040167566 @default.
• W4285590921 creator A5040237307 @default.
• W4285590921 creator A5050997539 @default.
• W4285590921 creator A5051978412 @default.
• W4285590921 creator A5053301712 @default.
• W4285590921 creator A5053417709 @default.
• W4285590921 creator A5054176247 @default.
• W4285590921 creator A5056089454 @default.
• W4285590921 creator A5056128918 @default.
• W4285590921 creator A5058800503 @default.
• W4285590921 creator A5059023087 @default.
• W4285590921 creator A5061972854 @default.
• W4285590921 creator A5063113707 @default.
• W4285590921 creator A5064937907 @default.
• W4285590921 creator A5065809957 @default.
• W4285590921 creator A5075285115 @default.
• W4285590921 creator A5079775543 @default.
• W4285590921 creator A5080516734 @default.
• W4285590921 creator A5081574419 @default.
• W4285590921 creator A5082404295 @default.
• W4285590921 creator A5083468863 @default.
• W4285590921 creator A5085022651 @default.
• W4285590921 creator A5088198148 @default.
• W4285590921 date "2022-07-22" @default.
• W4285590921 modified "2023-10-10" @default.
• W4285590921 title "Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022" @default.
• W4285590921 cites W3198593250 @default.
• W4285590921 cites W4206069935 @default.
• W4285590921 cites W4220921782 @default.
• W4285590921 cites W4225015742 @default.
• W4285590921 cites W4226246286 @default.
• W4285590921 cites W4226443227 @default.
• W4285590921 cites W4281489105 @default.
• W4285590921 cites W4281827985 @default.
• W4285590921 cites W4283319609 @default.
• W4285590921 doi "https://doi.org/10.15585/mmwr.mm7129e1" @default.
• W4285590921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35862287" @default.
• W4285590921 hasPublicationYear "2022" @default.
• W4285590921 type Work @default.
• W4285590921 citedByCount "82" @default.
• W4285590921 countsByYear W42855909212022 @default.
• W4285590921 countsByYear W42855909212023 @default.
• W4285590921 crossrefType "journal-article" @default.
• W4285590921 hasAuthorship W4285590921A5000178488 @default.
• W4285590921 hasAuthorship W4285590921A5004523264 @default.
• W4285590921 hasAuthorship W4285590921A5005759933 @default.
• W4285590921 hasAuthorship W4285590921A5005960274 @default.
• W4285590921 hasAuthorship W4285590921A5006012150 @default.
• W4285590921 hasAuthorship W4285590921A5006755486 @default.
• W4285590921 hasAuthorship W4285590921A5016019091 @default.
• W4285590921 hasAuthorship W4285590921A5016734595 @default.
• W4285590921 hasAuthorship W4285590921A5020349673 @default.
• W4285590921 hasAuthorship W4285590921A5020614173 @default.
• W4285590921 hasAuthorship W4285590921A5022164471 @default.
• W4285590921 hasAuthorship W4285590921A5027374619 @default.
• W4285590921 hasAuthorship W4285590921A5027395964 @default.
• W4285590921 hasAuthorship W4285590921A5028068827 @default.
• W4285590921 hasAuthorship W4285590921A5033960636 @default.
• W4285590921 hasAuthorship W4285590921A5034478332 @default.
• W4285590921 hasAuthorship W4285590921A5034545940 @default.
• W4285590921 hasAuthorship W4285590921A5037638028 @default.
• W4285590921 hasAuthorship W4285590921A5038160777 @default.
• W4285590921 hasAuthorship W4285590921A5040167566 @default.
• W4285590921 hasAuthorship W4285590921A5040237307 @default.
• W4285590921 hasAuthorship W4285590921A5050997539 @default.
• W4285590921 hasAuthorship W4285590921A5051978412 @default.
• W4285590921 hasAuthorship W4285590921A5053301712 @default.
• W4285590921 hasAuthorship W4285590921A5053417709 @default.
• W4285590921 hasAuthorship W4285590921A5054176247 @default.
• W4285590921 hasAuthorship W4285590921A5056089454 @default.
• W4285590921 hasAuthorship W4285590921A5056128918 @default.
• W4285590921 hasAuthorship W4285590921A5058800503 @default.
• W4285590921 hasAuthorship W4285590921A5059023087 @default.
• W4285590921 hasAuthorship W4285590921A5061972854 @default.
• W4285590921 hasAuthorship W4285590921A5063113707 @default.
• W4285590921 hasAuthorship W4285590921A5064937907 @default.
• W4285590921 hasAuthorship W4285590921A5065809957 @default.

• next